Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (51-60 of 435) with videos related to

Pageof 44
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2012
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemiaHun Ju Lee, Naval Daver, Hagop M Kantarjian, et al.
Leukemia & Lymphoma|July 14, 2022
Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemiaNaval Daver, Brian A Jonas, Bruno C Medeiros, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 23, 2021
Infectious Complications Among Patients With AML Treated With Immune Checkpoint InhibitorsAmy Spallone, Ahmad S Alotaibi, Ying Jiang, et al.
Blood Cancer Journal|June 10, 2022
Resistance to targeted therapies: delving into FLT3 and IDHSai Prasad Desikan, Naval Daver, Courtney DiNardo, et al.
Current Oncology Reports|August 1, 2025
Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive ChemotherapyAlex Bataller, Nicholas J Short, Naval Daver, et al.
Advances in Experimental Medicine and Biology|March 22, 2017
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AMLLucia Masarova, Hagop Kantarjian, Guillermo Garcia-Mannero, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 18, 2014
Pernicious anemia with spuriously normal vitamin B12 level might be misdiagnosed as myelodysplastic syndromeDhaval R Shah, Naval Daver, Gautam Borthakur, et al.
Advances in Experimental Medicine and Biology|December 13, 2018
Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical PracticeLucia Masarova, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia & Lymphoma|July 7, 2017
The emerging role of immune checkpoint based approaches in AML and MDSPrajwal Boddu, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 19, 2012
Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabinePavan Kumar Bhamidipati, Elias Jabbour, Sergej Konoplev, et al.
Pageof 44

Showing results (51-60 of 435) with videos related to

Sort By:
Pageof 44
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2012
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemiaHun Ju Lee, Naval Daver, Hagop M Kantarjian, et al.
Leukemia & Lymphoma|July 14, 2022
Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemiaNaval Daver, Brian A Jonas, Bruno C Medeiros, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 23, 2021
Infectious Complications Among Patients With AML Treated With Immune Checkpoint InhibitorsAmy Spallone, Ahmad S Alotaibi, Ying Jiang, et al.
Blood Cancer Journal|June 10, 2022
Resistance to targeted therapies: delving into FLT3 and IDHSai Prasad Desikan, Naval Daver, Courtney DiNardo, et al.
Current Oncology Reports|August 1, 2025
Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive ChemotherapyAlex Bataller, Nicholas J Short, Naval Daver, et al.
Advances in Experimental Medicine and Biology|March 22, 2017
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AMLLucia Masarova, Hagop Kantarjian, Guillermo Garcia-Mannero, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 18, 2014
Pernicious anemia with spuriously normal vitamin B12 level might be misdiagnosed as myelodysplastic syndromeDhaval R Shah, Naval Daver, Gautam Borthakur, et al.
Advances in Experimental Medicine and Biology|December 13, 2018
Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical PracticeLucia Masarova, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia & Lymphoma|July 7, 2017
The emerging role of immune checkpoint based approaches in AML and MDSPrajwal Boddu, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 19, 2012
Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabinePavan Kumar Bhamidipati, Elias Jabbour, Sergej Konoplev, et al.
Pageof 44